Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine

Janet H Ford1 Eli Lilly and Company, Indianapolis, IN 46225, USA, [email protected]Correspondence[email protected]

Shonda A Foster1 Eli Lilly and Company, Indianapolis, IN 46225, USA, [email protected]

Virginia L Stauffer1 Eli Lilly and Company, Indianapolis, IN 46225, USA, [email protected]

Dustin D Ruff1 Eli Lilly and Company, Indianapolis, IN 46225, USA, [email protected]

Sheena K Aurora1 Eli Lilly and Company, Indianapolis, IN 46225, USA, [email protected]

Jan Versijpt2 Department of Neurology – Headache and Facial Pain Clinic, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), 1090 Brussels, Belgium

Figures & data

Figure 1 Study design of Study CGAJ.

Notes: ^aPatients randomized to the 120 mg dose will receive a loading dose of 240 mg at the first injection only (Visit 2). ^bTelephone visit.
Abbreviation: SP, study period.

Table 1 Baseline demographics and clinical characteristics

Download CSV Display Table

Figure 2 Reduction in number of migraine headache days per month in patients with episodic migraine (A) and chronic migraine (B).

Notes: Results are LS mean change from baseline ± SE. ^{^}p<0.001; ^**p<0.01.
Abbreviations: GMB, galcanezumab; LS, least square; SE, standard error.

Table 2 Percentage of patients in the combined galcanezumab dose groups with positive responses on the Patient Satisfaction with Medication Questionnaire–Modified

Download CSV Display Table

Figure 3 Migraine-specific HCRU as count of persons with at least one visit (%) (A), and as per 100 patient-years (B) during baseline period and treatment period.

Notes: ^{^}p<0.0001, ^*p<0.01 for within-group differences from baseline. More statistical comparisons were not performed for the analysis in (A) and for the GMB all group in (B).
Abbreviations: ER, emergency room; GMB, galcanezumab; HCP, health care professional.

Figure 4 Change from baseline in number of days per month with acute medication use for migraine or headache. Changes at each month (A) and overall change (B) from baseline are shown.

Notes: Results are LS mean change ± SE from baseline. Significant within-group differences were noted in both the GMB dose groups at each month and overall, ^{^}p<0.001.
Abbreviations: GMB, galcanezumab; SE, standard error; LS, least squares.

Table S1 Breakdown of responses to the Patient Satisfaction with Medication Questionnaire–Modified by galcanezumab dose group and visit

Download CSV Display Table

Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine

Table 1 Baseline demographics and clinical characteristics

Table 2 Percentage of patients in the combined galcanezumab dose groups with positive responses on the Patient Satisfaction with Medication Questionnaire–Modified

Table S1 Breakdown of responses to the Patient Satisfaction with Medication Questionnaire–Modified by galcanezumab dose group and visit

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine

Figures & data

Table 1 Baseline demographics and clinical characteristics

Table 2 Percentage of patients in the combined galcanezumab dose groups with positive responses on the Patient Satisfaction with Medication Questionnaire–Modified

Table S1 Breakdown of responses to the Patient Satisfaction with Medication Questionnaire–Modified by galcanezumab dose group and visit

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date